# CYP3A4: Major Hepatic Drug-Metabolizing Enzyme, Active Site Plasticity, and Substrate Inhibition


## Key Takeaways

- CYP3A4, the most abundant hepatic drug-metabolizing enzyme, exhibits remarkable substrate promiscuity due to a large, flexible active site, enabling the metabolism of approximately 30-50% of clinically used drugs.
- Its transcriptional regulation is primarily governed by the xenobiotic sensor Pregnane X Receptor (PXR), which binds to a distal enhancer module (XREM) and cooperates with proximal promoter elements to achieve high-level inducible expression.
- The enzyme's active site plasticity allows it to accommodate diverse substrates through conformational rearrangements, a mechanism crucial for its broad substrate range but also contributing to substrate inhibition at high concentrations.
- Clinically relevant genetic variants, such as CYP3A4*22, can significantly alter enzyme activity and expression, impacting the pharmacokinetics of immunosuppressants like tacrolimus and increasing the risk of adverse drug reactions.
- Viral infections (e.g., HIV, HCV) and inflammatory cytokines can suppress CYP3A4 expression, leading to impaired drug clearance and potential drug-drug interactions, while certain antibiotics (e.g., rifampicin) and antifungals (e.g., ketoconazole) are potent inducers or inhibitors, respectively.

---

## Executive Summary & Key Metadata

Cytochrome P450 3A4 (CYP3A4) is the most abundant cytochrome P450 enzyme in the human liver and small intestine, responsible for the oxidative metabolism of approximately 30–50% of all clinically used drugs. Its extraordinary substrate promiscuity—ranging from small molecules like midazolam to macrocyclic antibiotics such as erythromycin and immunosuppressants like cyclosporine A—is enabled by a large, flexible, and conformationally dynamic active site. This manual provides a comprehensive, biophysically grounded reference for the genomic architecture, structural biology, molecular function, clinical [pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), and pathological associations of CYP3A4.

| **Metadata Field** | **Value** |
|---|---|
| **HGNC Symbol** | CYP3A4 |
| **UniProt Accession** | P08684 |
| **Representative PDB ID** | 1TQN (human CYP3A4 with progesterone bound) |
| **Chromosomal Locus** | 7q22.1 (GRCh38: chr7:99,756,967–99,784,184) |
| **Primary Molecular Function** | Heme-containing monooxygenase; NADPH-dependent oxidation of xenobiotics and endobiotics |
| **Disease & Pathology Associations** | Altered drug response phenotypes; susceptibility to drug-induced liver injury; potential modifier in hormone-dependent cancers; linked to tacrolimus and statin toxicity |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Genomic Context

The *CYP3A4* gene is located on the long arm of chromosome 7 at cytogenetic band 7q22.1. In the GRCh38 assembly, the gene spans approximately 27.2 kilobases (kb) from position 99,756,967 to 99,784,184 on the forward strand. The gene is embedded within the *CYP3A* cluster, a tandem array of four cytochrome P450 genes arranged in the following order on chromosome 7: *CYP3A4* → *CYP3A7* → *CYP3A5* → *CYP3A43* (from centromere to telomere). This cluster spans roughly 230 kb and shares significant sequence homology, indicating ancient duplication events. The proximity of these genes complicates genetic association studies, as [linkage disequilibrium](/knowledge/bioinformatics/linkage-disequilibrium-and-haplotype-mapping) across the cluster can confound the attribution of phenotypic effects to specific paralogs.

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of *CYP3A4* lacks a canonical TATA box but contains a GC-rich region and multiple binding sites for constitutive transcription factors. The proximal promoter (−200 to +1 relative to the transcription start site) harbors binding motifs for:

- **Sp1 (Specificity Protein 1):** Binds GC boxes and contributes to basal transcriptional activity.
- **C/EBPα (CCAAT/Enhancer-Binding Protein Alpha):** Essential for hepatocyte-specific expression.
- **HNF4α (Hepatocyte Nuclear Factor 4 Alpha):** Binds to a DR1-type nuclear receptor response element at −152 to −140, critical for liver-enriched expression.
- **PXR (Pregnane X Receptor, NR1I2):** The primary xenobiotic sensor. Upon ligand activation, PXR heterodimerizes with RXRα (Retinoid X Receptor Alpha) and binds to a distal enhancer module located at approximately −7.8 kb upstream (the xenobiotic-responsive enhancer module, XREM). The XREM also contains a binding site for the constitutive androstane receptor (CAR, NR1I3), providing a secondary pathway for induction.
- **GR (Glucocorticoid Receptor):** Glucocorticoids such as dexamethasone induce CYP3A4 expression via both direct GR binding and indirect upregulation of PXR.

The XREM is indispensable for robust induction. Deletion or mutation of the PXR-binding sites within the XREM abolishes rifampicin-mediated induction, demonstrating that distal enhancer elements cooperate with the proximal promoter to achieve high-level inducible expression.

### 1.3 Alternative Splicing and Isoforms

The *CYP3A4* gene comprises 13 exons and 12 introns. The canonical transcript (NM_017460.6) encodes a 502-amino-acid protein. Several alternatively spliced variants have been catalogued in Ensembl and RefSeq, although most are subject to nonsense-mediated decay or produce non-functional truncated proteins:

- **CYP3A4_v1 (canonical):** Full-length, catalytically active.
- **CYP3A4_v2:** Retains intron 1, introducing a premature stop codon; predicted to be non-functional.
- **CYP3A4_v3:** Skips exon 5, resulting in an in-frame deletion of 31 amino acids within the F-helix region; this variant, if translated, would likely disrupt substrate binding.
- **CYP3A4_v4:** Uses an alternative acceptor site in exon 8, leading to a frameshift and truncated protein.

None of the non-canonical splice variants have been demonstrated to produce catalytically active protein in vivo. The clinical significance of these transcripts remains unclear, but their existence underscores the complexity of CYP3A4 gene regulation.

### 1.4 Copy Number Variation and Structural Variants

Copy number variants (CNVs) involving the *CYP3A* cluster have been reported. Duplications of *CYP3A4* are rare but have been associated with ultra-rapid metabolism of CYP3A4 substrates. Conversely, deletions encompassing the entire cluster are embryonic lethal in model systems, though partial deletions have been observed in humans with reduced metabolic capacity. The clinical impact of CNVs is an active area of pharmacogenomic research.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Topology

CYP3A4 is a membrane-bound hemoprotein of 502 amino acids with a molecular weight of approximately 57.3 kDa. The protein adopts the canonical cytochrome P450 fold, consisting of 12 α-helices (designated A–L) and 4 β-sheets. The N-terminal region (residues 1–30) contains a hydrophobic transmembrane helix that anchors the protein to the cytoplasmic face of the endoplasmic reticulum (ER) membrane. A short proline-rich hinge region (residues 30–50) connects the membrane anchor to the globular catalytic domain.

The overall architecture can be divided into several functional regions:

- **Membrane Anchor (residues 1–30):** Single-pass transmembrane helix; essential for proper ER localization and interaction with NADPH-cytochrome P450 reductase (CPR).
- **Proline-Rich Hinge (residues 30–50):** Provides conformational flexibility and correct orientation of the catalytic domain relative to the membrane.
- **Substrate Recognition Sites (SRSs):** Six regions (SRS1–SRS6) distributed across the primary sequence that line the active site cavity. These correspond to the B–C loop (SRS1), F–G loop (SRS2), I-helix (SRS4), and β-sheet regions (SRS3, SRS5, SRS6).
- **Heme-Binding Domain (residues 430–502):** Contains the conserved FXXGXRXCXG motif (residues 441–450) with the invariant cysteine (Cys442) that serves as the fifth axial ligand to the heme iron. The heme prosthetic group is non-covalently bound but deeply buried within the protein core.
- **Cysteine Pocket:** The absolutely conserved Cys442 is essential for catalytic activity; mutation to serine or alanine abolishes monooxygenase function.

### 2.2 Active Site Plasticity and Conformational Dynamics

The defining structural feature of CYP3A4 is the remarkable plasticity of its active site. The substrate-binding cavity is large (approximately 1,000–2,000 ų) and lined predominantly by hydrophobic and aromatic residues, including Phe108, Phe213, Phe215, Phe220, Phe241, Phe304, and Phe309. This aromatic-rich environment facilitates π-stacking interactions with a wide range of aromatic and heteroaromatic substrates.

Crystallographic studies of CYP3A4 in different liganded states (e.g., PDB entries 1TQN, 2J0D, 3NXU, 4D6Z, 4D75) have revealed that the F–G helix bundle and the B–C loop undergo substantial conformational rearrangements upon substrate binding. In the progesterone-bound structure (1TQN), the active site adopts a closed conformation with the substrate positioned approximately 5 Å from the heme iron. In contrast, the ketoconazole-bound structure (2J0D) shows an open conformation where the F–G helices have moved outward, expanding the cavity to accommodate the larger inhibitor.

This conformational flexibility is not merely a static property but is dynamically sampled in solution. Hydrogen-deuterium exchange mass spectrometry (HDX-MS) studies demonstrate that the F–G loop and the I-helix exhibit high conformational exchange rates, allowing the enzyme to adapt to substrates of varying size and shape. This "substrate-induced fit" mechanism explains the enzyme's ability to oxidize molecules as small as acetaminophen (151 Da) and as large as cyclosporine A (1,203 Da).

### 2.3 Heme Coordination and Oxygen Activation

The heme iron is coordinated by four pyrrole nitrogen atoms of the protoporphyrin IX ring and the thiolate sulfur of Cys442 as the fifth (proximal) ligand. The sixth (distal) coordination site is vacant in the resting state, allowing molecular oxygen to bind after substrate-induced reduction of the iron from Fe³⁺ to Fe²⁺. The catalytic cycle proceeds through the following steps:

1. **Substrate binding:** Displaces a water molecule from the distal pocket, altering the redox potential of the heme iron.
2. **First electron transfer:** CPR transfers an electron from NADPH to the heme iron, reducing Fe³⁺ to Fe²⁺.
3. **Oxygen binding:** Molecular oxygen binds to the ferrous heme, forming a ferric-superoxide complex.
4. **Second electron transfer:** A second electron (from CPR or cytochrome b5) reduces the dioxygen adduct to a ferric-peroxo species.
5. **Protonation and O–O bond cleavage:** Two protons are delivered to the distal oxygen, leading to heterolytic cleavage of the O–O bond and formation of a highly reactive Compound I (Fe⁴⁺=O porphyrin π-cation radical).
6. **Substrate oxidation:** Compound I abstracts a hydrogen atom from the substrate, followed by oxygen rebound to form the hydroxylated product.
7. **Product release:** The oxidized product dissociates, and a water molecule re-binds to the heme iron, returning the enzyme to its resting state.

The thiolate ligand (Cys442) is critical for this process; it imparts a "push" effect that stabilizes the high-valent iron-oxo intermediate and facilitates O–O bond cleavage.

### 2.4 Structural Determinants of Substrate Inhibition

Substrate inhibition—a phenomenon where high substrate concentrations reduce the rate of metabolism—is a hallmark of CYP3A4 kinetics. Structural studies suggest that this arises from the binding of a second substrate molecule within the active site cavity in a non-productive orientation. The large cavity can accommodate two molecules simultaneously; the second molecule may occupy a position that blocks the access of the first molecule to the heme iron or alters the conformation of the I-helix, impairing oxygen activation. Kinetic models, including the two-site Michaelis-Menten model and the allosteric model, have been proposed to describe this behavior. The physiological relevance of substrate inhibition is debated, but it may protect against excessive formation of reactive metabolites at high substrate concentrations.

### 2.5 Interactive 3D Visualization

> **Interactive 3D Protein Visualizer: Load CYP3A4 (PDB: 1TQN)**  
> [Launch the interactive 3D viewer](/tools/protein-structure-viewer?source=direct&pdbId=1TQN)  
> This tool allows you to rotate the structure, highlight the heme prosthetic group, visualize the F–G helix bundle, and measure distances between key catalytic residues. Use the "Ligand" layer to display the bound progesterone molecule and the "Membrane" layer to approximate the ER membrane plane.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Cytochrome P450 Catalytic Cycle and Electron Transfer

CYP3A4 functions as the terminal oxidase in a two-protein electron transfer chain located on the cytoplasmic face of the ER membrane. The obligate redox partner is **NADPH-cytochrome P450 reductase (CPR)**, a flavoprotein that contains both FAD and FMN cofactors. CPR transfers electrons from NADPH to the heme iron of CYP3A4 in two discrete steps, as described in Section 2.3. A second accessory protein, **cytochrome b5**, can donate the second electron in some reactions, enhancing catalytic efficiency for certain substrates.

The interaction between CYP3A4 and CPR is electrostatic and dynamic. The basic residues on the proximal face of CYP3A4 (e.g., Arg130, Arg136, Lys421) interact with acidic residues on the FMN-binding domain of CPR. This interaction is transient; CPR must dissociate and re-associate for each electron transfer event, making the complex stoichiometry and membrane diffusion kinetics important determinants of overall metabolic flux.

### 3.2 Transcriptional Regulation and Nuclear Receptor Signaling

CYP3A4 expression is regulated at the transcriptional level by a network of nuclear receptors that sense both endogenous and exogenous ligands:

- **Pregnane X Receptor (PXR, NR1I2):** The master regulator of CYP3A4 induction. PXR is activated by a structurally diverse array of compounds, including rifampicin, hyperforin (from St. John's Wort), paclitaxel, and numerous steroids. Upon ligand binding, PXR translocates to the nucleus, heterodimerizes with RXRα, and binds to the XREM and proximal promoter response elements, recruiting coactivators such as SRC-1 and PGC-1α.
- **Constitutive Androstane Receptor (CAR, NR1I3):** Shares overlapping response elements with PXR and can induce CYP3A4 in response to phenobarbital and other compounds. CAR is retained in the cytoplasm in its inactive state and translocates to the nucleus upon activation.
- **Glucocorticoid Receptor (GR):** Dexamethasone and other glucocorticoids induce CYP3A4, partly through direct GR binding and partly through transcriptional upregulation of PXR.
- **Vitamin D Receptor (VDR):** In intestinal epithelial cells, VDR activation by 1,25-dihydroxyvitamin D3 induces CYP3A4 expression, contributing to first-pass metabolism of orally administered drugs.
- **Hepatocyte Nuclear Factor 4α (HNF4α):** A master regulator of hepatocyte differentiation that maintains basal CYP3A4 expression by binding to the proximal promoter.

### 3.3 Endogenous Substrates and Physiological Roles

Beyond xenobiotic metabolism, CYP3A4 participates in the oxidative metabolism of numerous endogenous compounds:

- **Steroid Hormones:** CYP3A4 catalyzes the 6β-hydroxylation of testosterone, cortisol, and progesterone. This is a major pathway for steroid clearance. The 6β-hydroxycortisol to cortisol ratio in urine is used as a non-invasive biomarker of CYP3A4 activity.
- **Bile Acids:** CYP3A4 hydroxylates lithocholic acid and other hydrophobic bile acids, facilitating their elimination.
- **Retinoic Acid:** CYP3A4 oxidizes all-trans-retinoic acid to 4-hydroxy-retinoic acid, regulating retinoid signaling.
- **Cholesterol:** CYP3A4 contributes to the 4β-hydroxylation of cholesterol, a minor but measurable pathway.

### 3.4 Protein-Protein Interaction Networks

CYP3A4 engages in several protein-protein interactions beyond its redox partners:

- **Cytochrome b5:** Modulates the kinetics of certain CYP3A4-catalyzed reactions, particularly those requiring a second electron.
- **Cytochrome P450 3A5 (CYP3A5):** Co-expression in the ER can lead to heteromeric complex formation, potentially altering substrate specificity and kinetics.
- **Heat Shock Protein 90 (HSP90) and Co-chaperones:** In the absence of heme, apo-CYP3A4 is stabilized by HSP90 and the co-chaperone p23, which facilitate heme insertion.
- **Ubiquitin Ligases (e.g., gp78, CHIP):** CYP3A4 is subject to ubiquitin-proteasome degradation. The E3 ligase gp78 (also known as RNF45) ubiquitinates CYP3A4, targeting it for ER-associated degradation (ERAD). This pathway is accelerated by oxidative stress and certain xenobiotics.

STRING and BioGRID databases list over 50 physical and functional interactors for CYP3A4, including metabolic enzymes, transporters, and transcription factors.

### 3.5 Mermaid Diagram: CYP3A4 Induction and Catalytic Cycle

```mermaid
sequenceDiagram
    participant Ligand as "Xenobiotic (e.g., Rifampicin)"
    participant PXR as "PXR (NR1I2)"
    participant RXR as "RXRα"
    participant XREM as "XREM Enhancer"
    participant Gene as "CYP3A4 Gene"
    participant mRNA as "CYP3A4 mRNA"
    participant ER as "ER Membrane"
    participant CPR as "NADPH-CPR"
    participant Heme as "CYP3A4-Heme"
    participant Sub as "Substrate"
    participant Prod as "Oxidized Product"
    Ligand->>PXR: Binds to ligand-binding domain
    PXR->>RXR: Heterodimerization
    PXR->>XREM: Nuclear translocation & DNA binding
    XREM->>Gene: Recruitment of coactivators (SRC-1, PGC-1α)
    Gene->>mRNA: Transcription activation
    mRNA->>ER: Translation & membrane insertion
    ER->>Heme: Heme incorporation
    CPR->>Heme: Electron transfer (NADPH → FAD → FMN → heme)
    Sub->>Heme: Substrate binding to active site
    Heme->>Prod: Oxygen activation & monooxygenation
    Prod-->>CPR: Product release & enzyme reset
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Catalog of Clinically Relevant Variants

The *CYP3A4* gene is highly polymorphic, with over 40 star (*) alleles catalogued by the Pharmacogene Variation (PharmVar) Consortium. Most variants are single nucleotide polymorphisms (SNPs) in non-coding regions or synonymous coding changes with minimal functional impact. However, several non-synonymous variants alter enzyme activity, stability, or substrate specificity.

| **Variant (rsID)** | **Protein Change** | **Allele** | **Functional Consequence** | **Clinical Association** |
|---|---|---|---|---|
| rs2740574 | Intronic (IVS10+12G>A) | *1B | Increased transcriptional activity (linked to PXR binding site) | Modest increase in CYP3A4 expression; variable clinical impact |
| rs4986910 | Leu293Pro | *3 | Reduced protein stability; decreased expression | Reduced metabolism of certain substrates; possible increased toxicity |
| rs55951658 | Ile118Val | *4 | Minimal effect on activity | No clear clinical phenotype |
| rs28371759 | Pro218Leu | *5 | Reduced catalytic activity | Impaired metabolism of midazolam and testosterone |
| rs4646438 | Arg162Gln | *6 | Reduced expression and activity | Associated with altered tacrolimus pharmacokinetics |
| rs72552799 | Gly56Asp | *8 | Reduced activity | Rare; potential impact on drug clearance |
| rs12721634 | Ser222Pro | *10 | Reduced activity | Rare; associated with decreased nifedipine oxidation |
| rs4986908 | Thr363Met | *12 | Reduced activity | Rare; potential impact on statin metabolism |
| rs12721627 | Pro416Leu | *13 | Reduced activity | Rare; potential impact on immunosuppressant metabolism |
| rs56324128 | Asp174His | *17 | Reduced activity | Rare; possible increased risk of drug-induced liver injury |

### 4.2 Structural Basis of Pathogenic Mutations

The functional impact of non-synonymous variants can be rationalized by their position within the three-dimensional structure:

- **Leu293Pro (*3):** Leu293 is located in the I-helix, a region critical for oxygen activation and proton transfer. The introduction of a proline residue introduces a kink in the helix, destabilizing the protein and reducing holo-enzyme levels.
- **Pro218Leu (*5):** Pro218 lies within the F–G loop, a region that undergoes conformational changes during substrate binding. Substitution to leucine alters the flexibility of this loop, impairing the enzyme's ability to accommodate substrates.
- **Gly56Asp (*8):** Gly56 is in the proline-rich hinge region connecting the membrane anchor to the catalytic domain. Substitution to aspartate introduces a charged residue that may disrupt membrane interaction or protein folding.
- **Thr363Met (*12):** Thr363 is located in the K-helix, near the ERR (ER retention) motif. Mutation to methionine may affect protein stability and heme incorporation.

### 4.3 Clinical Differentials and Disease Associations

CYP3A4 variants are not typically associated with Mendelian diseases. Instead, they act as modifiers of drug response and toxicity risk:

- **Immunosuppressants (Tacrolimus, Cyclosporine):** CYP3A4*1B and *22 (a promoter variant, rs35599367) have been associated with altered tacrolimus dose requirements in kidney and liver transplant recipients. The *22 allele reduces CYP3A4 expression and is associated with higher tacrolimus blood concentrations and increased nephrotoxicity risk.
- **Statins (Simvastatin, Atorvastatin):** Reduced-function CYP3A4 variants increase the risk of statin-induced myopathy and rhabdomyolysis due to elevated systemic exposure.
- **Opioids (Fentanyl, Oxycodone):** CYP3A4 is the primary metabolizing enzyme for these drugs. Reduced-function variants may lead to prolonged analgesia and respiratory depression.
- **Hormone-Dependent Cancers:** CYP3A4 catalyzes the oxidative inactivation of estradiol and testosterone. Altered CYP3A4 activity has been proposed as a modifier of breast and prostate cancer risk, although epidemiological studies have yielded inconsistent results.
- **Drug-Induced Liver Injury (DILI):** Certain CYP3A4 variants may increase the formation of reactive metabolites from drugs such as troglitazone and nefazodone, predisposing individuals to hepatotoxicity.

### 4.4 ClinVar Classification and Population Frequencies

Most CYP3A4 variants are classified as "Benign" or "Likely Benign" in ClinVar, reflecting their modest effects on enzyme activity. The *22 variant (rs35599367) is classified as "Pathogenic" for tacrolimus metabolism phenotype by some expert panels, although it is not disease-causing in the traditional sense. Population frequencies vary significantly across ethnic groups; for example, the *1B allele is more common in individuals of African ancestry (approximately 50–70%) than in Europeans (approximately 5–10%).

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Modulation of CYP3A4 Expression

Several viral infections and viral proteins have been shown to downregulate CYP3A4 expression, leading to clinically significant drug-drug interactions:

- **Human Immunodeficiency Virus (HIV):** HIV protease inhibitors (e.g., ritonavir, nelfinavir) are potent mechanism-based inactivators of CYP3A4. Ritonavir, in particular, is used as a pharmacokinetic booster for other protease inhibitors due to its ability to irreversibly inhibit CYP3A4. HIV infection itself, via the pro-inflammatory cytokine milieu (e.g., IL-6, TNF-α), suppresses CYP3A4 expression through downregulation of PXR and HNF4α.
- **Hepatitis C Virus (HCV):** Chronic HCV infection reduces hepatic CYP3A4 activity, likely through interferon-mediated suppression of nuclear receptor signaling. Direct-acting antiviral agents (DAAs) such as grazoprevir are substrates and inhibitors of CYP3A4, necessitating careful dose adjustments.
- **Cytomegalovirus (CMV):** CMV infection in transplant recipients has been associated with reduced CYP3A4 activity, potentially contributing to calcineurin inhibitor toxicity.

### 5.2 Bacterial and Fungal Interactions

- **Mycobacterium tuberculosis:** Rifampicin, a first-line anti-tuberculosis drug, is the prototypical CYP3A4 inducer. Rifampicin activates PXR, leading to a 3- to 5-fold increase in CYP3A4 expression. This induction is responsible for numerous clinically significant drug-drug interactions, including reduced efficacy of oral contraceptives, warfarin, and many antiretrovirals.
- **Fungal Infections:** Ketoconazole and itraconazole are potent CYP3A4 inhibitors used to treat systemic fungal infections. Their inhibition of CYP3A4 is the basis for many contraindicated drug combinations.

### 5.3 Immune Evasion and Inflammatory Signaling

Pro-inflammatory cytokines, particularly IL-6, IL-1β, and TNF-α, downregulate CYP3A4 expression through multiple mechanisms:

- **Suppression of PXR and CAR expression:** Cytokine signaling via JAK/STAT and NF-κB pathways reduces the abundance of these nuclear receptors.
- **Post-translational modifications:** IL-6 induces the ubiquitination and proteasomal degradation of CYP3A4 protein.
- **MicroRNA-mediated regulation:** miR-27b and miR-206 have been shown to target CYP3A4 mRNA, and their expression is modulated by inflammatory stimuli.

This inflammation-mediated downregulation is clinically relevant in conditions such as sepsis, rheumatoid arthritis, and cancer cachexia, where drug clearance is often impaired.

---

## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors

### 6.1 CYP3A4 as a Drug Target

CYP3A4 is not a therapeutic target in the conventional sense (i.e., it is not a disease-causing protein). However, its inhibition or induction is a major consideration in drug development and clinical practice. The FDA and EMA require evaluation of CYP3A4 inhibition and induction potential for all new molecular entities.

### 6.2 FDA-Approved Drugs That Inhibit CYP3A4

| **Drug** | **Class** | **Inhibition Type** | **Clinical Use** |
|---|---|---|---|
| **Ritonavir** | HIV protease inhibitor | Mechanism-based (irreversible) | HIV treatment; pharmacokinetic booster |
| **Ketoconazole** | Azole antifungal | Reversible, competitive | Systemic fungal infections |
| **Itraconazole** | Azole antifungal | Reversible, competitive | Systemic fungal infections |
| **Clarithromycin** | Macrolide antibiotic | Mechanism-based | Respiratory tract infections |
| **Grapefruit juice (bergamottin)** | Natural product | Mechanism-based | Dietary interaction |
| **Cobicistat** | Pharmacokinetic enhancer | Mechanism-based | HIV treatment (boosting) |
| **Nefazodone** | Antidepressant | Reversible | Major depressive disorder |
| **Verapamil** | Calcium channel blocker | Reversible | Hypertension, angina |

### 6.3 FDA-Approved Drugs That Induce CYP3A4

| **Drug** | **Class** | **Induction Mechanism** | **Clinical Use** |
|---|---|---|---|
| **Rifampicin** | Antibiotic (rifamycin) | PXR activation | Tuberculosis, leprosy |
| **Carbamazepine** | Anticonvulsant | PXR/CAR activation | Epilepsy, bipolar disorder |
| **Phenytoin** | Anticonvulsant | CAR activation | Epilepsy |
| **Phenobarbital** | Barbiturate | CAR activation | Epilepsy |
| **St. John's Wort (hyperforin)** | Herbal supplement | PXR activation | Depression |
| **Dexamethasone** | Corticosteroid | GR/PXR activation | Inflammation, immunosuppression |

### 6.4 Investigational Small Molecules and Biologics

- **CYP3A4-selective inhibitors:** Several highly selective inhibitors have been developed as research tools, including **CYP3cide** (a mechanism-based inhibitor) and **azamulin**. These compounds are used to delineate CYP3A4-specific contributions in drug metabolism studies.
- **Gene therapy approaches:** While no gene therapy targeting CYP3A4 is in clinical trials, preclinical studies have explored the use of antisense oligonucleotides (ASOs) and short hairpin RNAs (shRNAs) to knockdown CYP3A4 expression in animal models of drug toxicity.
- **Monoclonal antibodies:** Anti-CYP3A4 antibodies have been developed for research purposes, primarily for immunoquantification and activity inhibition assays. No therapeutic antibodies targeting CYP3A4 are in development.

### 6.5 Pharmacogenomic Testing and Clinical Implementation

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published guidelines for CYP3A4 genotype-guided dosing of tacrolimus. The *22 allele (rs35599367) is associated with reduced CYP3A4 expression and is used to guide initial tacrolimus dosing in transplant recipients. However, CYP3A5 genotype is a stronger predictor of tacrolimus pharmacokinetics, and guidelines recommend considering both genes together.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 1576 | https://www.ncbi.nlm.nih.gov/gene/1576 |
| **Ensembl** | ENSG00000160868 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000160868 |
| **UniProt** | P08684 | https://www.uniprot.org/uniprotkb/P08684 |
| **RCSB PDB** | 1TQN (and others: 2J0D, 3NXU, 4D6Z, 4D75) | https://www.rcsb.org/structure/1TQN |
| **ClinVar** | Gene: CYP3A4 | https://www.ncbi.nlm.nih.gov/clinvar/?term=CYP3A4 |
| **PharmVar** | CYP3A4 | https://www.pharmvar.org/gene/CYP3A4 |
| **PharmGKB** | PA128 | https://www.pharmgkb.org/gene/PA128 |
| **STRING** | 9606.ENSP00000263507 | https://string-db.org/ |
| **BioGRID** | 108028 | https://thebiogrid.org/ |
| **Gene Ontology (GO)** | GO:0004497 (monooxygenase activity); GO:0005506 (iron ion binding); GO:0020037 (heme binding); GO:0016705 (oxidoreductase activity, acting on paired donors) | https://www.ebi.ac.uk/QuickGO/ |
| **Reactome** | R-HSA-211945 (Phase I - Functionalization of compounds) | https://reactome.org/ |
| **KEGG** | hsa:1576 | https://www.genome.jp/dbget-bin/www_bget?hsa:1576 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Guengerich FP. "Cytochrome P450 3A4: Regulation and Role in Drug Metabolism." *Annual Review of Pharmacology and Toxicology*. 1999;39:1-17. doi:10.1146/annurev.pharmtox.39.1.1.
2. Williams PA, Cosme J, Vinkovic DM, et al. "Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone." *Science*. 2004;305(5684):683-686. doi:10.1126/science.1099736.
3. Ekroos M, Sjögren T. "Structural Basis for Ligand Promiscuity in Cytochrome P450 3A4." *Proceedings of the National Academy of Sciences USA*. 2006;103(37):13682-13687. doi:10.1073/pnas.0603237103.
4. Sevrioukova IF, Poulos TL. "Understanding the Mechanism of Cytochrome P450 3A4: Recent Advances and Remaining Problems." *Dalton Transactions*. 2013;42(9):3116-3126. doi:10.1039/c2dt31833d.
5. Zanger UM, Schwab M. "Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation." *Pharmacology & Therapeutics*. 2013;138(1):103-141. doi:10.1016/j.pharmthera.2012.12.007.
6. Lamba JK, Lin YS, Schuetz EG, Thummel KE. "Genetic Contribution to Variable Human CYP3A-Mediated Metabolism." *Advanced Drug Delivery Reviews*. 2002;54(10):1271-1294. doi:10.1016/s0169-409x(02)00066-5.
7. Hustert E, Haberl M, Burk O, et al. "The Genetic Determinants of the CYP3A5 Polymorphism." *Pharmacogenetics*. 2001;11(9):773-779. doi:10.1097/00008571-200112000-00005.
8. Klein K, Thomas M, Winter S, et al. "PPARA: A Novel Transgenic Target for CYP3A4 Induction." *Pharmacogenetics and Genomics*. 2012;22(6):431-440. doi:10.1097/FPC.0b013e3283534d7e.
9. Wang D, Sadee W. "CYP3A4 Intronic SNP rs35599367 (CYP3A4*22) Alters RNA Splicing and CYP3A4 Protein Expression." *Pharmacogenetics and Genomics*. 2016;26(6):289-297. doi:10.1097/FPC.0000000000000217.
10. Bird JE, Walsh RJ, Howe R, et al. "CYP3A4*22 and CYP3A5*3 Genotype-Guided Tacrolimus Dosing in Renal Transplant Recipients." *American Journal of Transplantation*. 2017;17(5):1245-1252. doi:10.1111/ajt.14107.
11. Denisov IG, Makris TM, Sligar SG, Schlichting I. "Structure and Chemistry of Cytochrome P450." *Chemical Reviews*. 2005;105(6):2253-2277. doi:10.1021/cr0307143.
12. Scott EE, Halpert JR. "Structures of Cytochrome P450 3A4." *Trends in Biochemical Sciences*. 2005;30(1):5-7. doi:10.1016/j.tibs.2004.11.004.
13. Davydov DR, Halpert JR, Renaud JP, Hui Bon Hoa G. "Conformational Heterogeneity in Cytochrome P450 3A4 as a Basis for Substrate Binding and Catalytic Diversity." *Biochemistry*. 2003;42(2):413-422. doi:10.1021/bi026850h.
14. Aoyama T, Yamano S, Waxman DJ, et al. "Cytochrome P-450 hPCN3, a Novel Cytochrome P-450 IIIA Gene Product That Is Differentially Expressed in Adult Human Liver." *Journal of Biological Chemistry*. 1989;264(18):10388-10395.
15. Goodwin B, Hodgson E, Liddle C. "The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module." *Molecular Pharmacology*. 1999;56(6):1329-1339. doi:10.1124/mol.56.6.1329.
16. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. "The Human Orphan Nuclear Receptor PXR Is Activated by Compounds That